Ann-Cathrin Jareman

Ann-Cathrin Jareman

Office

Stockholm

Region Covered

Scandinavia

Email

ajareman@ppi.consulting


Ann-Cathrin is the PPi HC representative for the Nordic markets.

She supports market Access activities for PPi in Sweden, Denmark, Norway, Finland and Iceland.

She  has a 20 years experience with pharmaceutical;  as well as with medical devices including IVDs.  Ann-Cathrin’s experience ranges from development of market access strategies to  dossier submissions for market clearance. She is also familiar with setting up quality systems for medical devices, including IVDs as well as overall project management.

Ann-Cathrin has an educational background in chemical engineering.

About

TESTIMONIALS

With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project. Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!

Thomas W. MacAllister JD, PhD,Vice President of R&D and General Counsel, Remedy Pharmaceuticals